Alkem Laboratories Ltd (ALKEM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Alkem Laboratories Ltd (ALKEM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH133542D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Alkem Laboratories Ltd (Alkem) is a pharmaceutical company that develops, manufactures and markets generic and specialty pharmaceutical products. The company's products include active pharmaceutical ingredients, generic products, branded products and nutraceuticals. Alkem provides drugs for acute and chronic diseases such as central nervous system disorders, gastro-intestinal infections, diabetes, malaria, pain, cardiovascular diseases and immune disorders. It offers vitamins, minerals and nutrition products. The company distributes its products through a wide network of distributors all over India. It exports products to Europe, Australia, South-East Asia, North America, South America, Russia-CIS and Africa. Alkem is headquartered in Mumbai, Maharashtra, India.

Alkem Laboratories Ltd (ALKEM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Alkem Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Alkem Labs Acquires Formulation Manufacturing Facility from Long Pharma 13

Alkem Labs Acquires Manufacturing Assets from NORAC 14

Partnerships 15

Alkem Labs Enters into Agreement with Haw Par 15

Licensing Agreements 16

Alkem Labs Enters into Licensing Agreement with Stempeutics Research 16

Alkem Enters into Licensing Agreement with MediPost for Cartistem 17

Dong-A Pharma Enters Into Licensing Agreement With Alkem Labs For DA-1229 18

Equity Offering 19

Alkem Labs Raises USD202 Million in IPO 19

Asset Transactions 21

Ordain Health Care Acquires Fertica Business from Alkem Labs for USD4 Million 21

Acquisition 22

Alkem Labs Acquires 51% Stake in Cachet Pharma 22

Alkem Labs Acquires 51% Stake in Indchemie Health Specialities 23

Alkem Labs Acquires Remaining 20% Stake in Enzene Biosciences 24

Alkem Labs Acquires Remaining 80% Stake in Pharmacor from S&B 25

Alkem Laboratories Ltd-Key Competitors 26

Alkem Laboratories Ltd-Key Employees 27

Alkem Laboratories Ltd-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 30

Financial Announcements 30

May 30, 2018: Alkem reports Q4FY18 and FY18 Results 30

Aug 11, 2017: Alkem Reports Q1FY18 Results 32

Corporate Communications 33

Oct 31, 2017: Alkem Laboratories: Resignation of Chief Executive Officer (CEO) 33

May 17, 2017: Alkem Laboratories Announces resignation of Independent Director 34

Legal and Regulatory 35

Aug 11, 2018: Alkem Laboratories provides update on the US FDA Inspection at Manufacturing Facility at California, USA 35

Aug 10, 2018: Update on US FDA inspection at Alkem's Baddi Facility 36

Jul 24, 2018: Alkem receives EIR from the US FDA for its Daman formulation facility 37

Mar 28, 2018: Alkem Labs: Update on USFDA Inspection at its manufacturing facility at Amaliya in India 38

Jan 10, 2018: Update on US FDA Inspection at Alkem's Baddi Facility 39

Jan 10, 2018: Alkem receives EIR from the US FDA for its Baddi formulation facility 40

Oct 28, 2017: US FDA completes inspection at Alkem Laboratories's St Louis facility 41

Sep 18, 2017: Alkem Announces Update on US FDA Inspection at Alkem's Baddi Facility 42

Jul 14, 2017: Update on US FDA inspection for Bioequivalence Facility at Taloja 43

May 23, 2017: Alkem receives EIR from the US FDA for its Baddi Management Manufacturing Facility 44

Mar 29, 2017: Alkem receives EIR from the US FDA for its Alkem's Ankaleshwar API Facility 45

Mar 10, 2017: Alkem Laboratories Announces Update on US FDA Inspection at Alkem s Baddi Facility 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Alkem Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 11

List of Tables

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alkem Laboratories Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Alkem Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Alkem Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Alkem Labs Acquires Formulation Manufacturing Facility from Long Pharma 13

Alkem Labs Acquires Manufacturing Assets from NORAC 14

Alkem Labs Enters into Agreement with Haw Par 15

Alkem Labs Enters into Licensing Agreement with Stempeutics Research 16

Alkem Enters into Licensing Agreement with MediPost for Cartistem 17

Dong-A Pharma Enters Into Licensing Agreement With Alkem Labs For DA-1229 18

Alkem Labs Raises USD202 Million in IPO 19

Ordain Health Care Acquires Fertica Business from Alkem Labs for USD4 Million 21

Alkem Labs Acquires 51% Stake in Cachet Pharma 22

Alkem Labs Acquires 51% Stake in Indchemie Health Specialities 23

Alkem Labs Acquires Remaining 20% Stake in Enzene Biosciences 24

Alkem Labs Acquires Remaining 80% Stake in Pharmacor from S&B 25

Alkem Laboratories Ltd, Key Competitors 26

Alkem Laboratories Ltd, Key Employees 27

Alkem Laboratories Ltd, Subsidiaries 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Alkem Laboratories Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17845
Site License
USD 500 INR 35690
Corporate User License
USD 750 INR 53535

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com